Tamoxifen manufacturer 10540-29-1 Tamoxifen supplier
Hanways Chempharm Co., Limited, the former is Hubei Hanways Pharchem CO.,Limited, set up in 2009 in Wuhan, China. We specialize in sourcing and supplying APIs, pharmaceutical intermediates, and fine chemicals for worldwide markets.
The founder has decades experience in pharmaceutical industry. We are not just a trading company, but a comprehensive solutions supplier. With our sound knowledge of pharmaceutical business, to integrate resource and adapt to all different demands of markets is our advantage. We are a small but dynamic and energetic company with high efficient and high flexible decision making system.
Our products cover oncology APIs and intermediates, antiviral APIs and intermediates, cardiovascular APIs and intermediates, hormones APIs and intermediates and so on. Cater to the developing of pharmaceutical industry, we focus on the niche and new compounds.
Our business philosophy is customer-oriented, reliability and trustworthy, better service and win-win. We will take every effort to supply quality products to seek mutual development and benefits.
Brief Description
Product name |
Tamoxifen |
Synonyms |
tamoxifen free base; Genox; Kessar; Nolvadex; Nolvadex-D; Tamoxen; (Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine; 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt); 2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine |
MOQ |
25KG |
CAS No. |
10540-29-1 |
Appearance |
An almost white powder |
Molecular Formula |
C26H29NO |
Molecular Weight |
371.5146 |
Assay |
99% |
Application |
Pharma grade or research purpose |
Packing |
As per your request |
Storage |
Preserve in tight, light-resistant containers in a cool place |
Remarks |
NA |
Custom synthesis |
Available |
Supply Ability |
10000kg/month |
Medical use
Breast cancer
Tamoxifen is currently used for the treatment of both early and advanced estrogen receptor-positive (ER-positive or ER+) breast cancer in pre- and post-menopausal women. Additionally, it is the most common hormone treatment for male breast cancer. It is also approved by the FDA for the prevention of breast cancer in women at high risk of developing the disease. It has been further approved for the reduction of contralateral (in the opposite breast) cancer. The use of tamoxifen is recommended for 10 years.
In 2006, the large STAR clinical study concluded that raloxifene is equally effective in reducing the incidence of breast cancer, but after an average 4-year follow-up, although the difference was not statistically significant, there were 36% fewer uterine cancers and 29% fewer blood clots in women taking raloxifene than in women taking tamoxifen.
Infertility
Tamoxifen is used to treat infertility in women with anovulatory disorders. It is given at days 3 to 7 of a woman's cycle.
Tamoxifen improves fertility in males with infertility by disinhibiting the hypothalamic–pituitary–gonadal axis (HPG axis) via ER antagonism and thereby increasing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) and increasing testicular testosterone production.
Gynecomastia
Tamoxifen is used to prevent or treat gynecomastia. It is taken as a preventative measure in small doses, or used at the onset of any symptoms such as nipple soreness or sensitivity. Other drugs are taken for similar purposes such as clomifene and the anti-aromatase drugs which are used in order to try to avoid the hormone-related adverse effects.
Others
Occasionally tamoxifen is used in treatment of the rare conditions of retroperitoneal fibrosis and idiopathic sclerosing mesenteritis.
Our Factory:
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View